Company Overview and News

 
Alkem to take maximum hit from combination drug ban: Nomura

2018-09-14 thehindubusinessline
Alkem Laboratories will take a maximum hit from the government’s decision to ban 328 combination drugs, says Nomura.
IPCALAB 524494 ALKEM 539523

 
LT Infotech, Kwality, Infosys, Greaves Cotton, HCL Tech top gainers among A group stocks

2018-09-04 moneycontrol
The market sentiment turned negative yet gain this Tuesday afternoon with the Nifty50 trading at 11,529, down 53 points while the Sensex is trading lower by 112 points at 38,199.
IPCALAB HCTHY 532504 532713 532710 532221 524494 SONATSOFTW HCLTECH 501455 NAVINFLUOR 532281 SADBHAV SAKUMA GREAVESCOT

 
IPCA Laboratories Limited - Shareholders meeting

2018-08-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Shareholders meeting

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Financial Result Updates

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Shareholders meeting

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Book Closure

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Allotment of ESOP/ESPS

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Dividend

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

 
IPCA Laboratories Limited - Financial Result Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IPCALAB 524494

23
Market Live: Sensex rangebound, PSU Bank index loses 2%; BHEL up 9% on Q4 nos

2018-05-29 moneycontrol
Market Update: Benchmark indices as well as broader markets are in a consolidation mode after sharp rally seen in previous three consecutive sessions. Investors closely monitor the movement in crude oil prices and rupee.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD 519183 GREENPLY HDFCBANK RLNIY IPCALAB 524804 IBN 538835 BHEL 539207 532531 ICICIBANK 524494 HDB 532174 500180 ARBQY 526797 BRHTY INTELLECT 500103 RECLTD MANPASAND ADFFOODS

20
Market Live: Nifty reclaims 10,700 amid weaker rupee; Vista Pharma up 10%

2018-05-29 moneycontrol
Market Update: The market continued to consolidate after rallying sharply in previous three consecutive sessions. Investors keenly monitor the movement in crude oil prices and rupee.
500325 AUROPHARMA RELIANCE 532955 532712 533106 RCOM OIL RIGD 519183 GREENPLY HDFCBANK RLNIY IPCALAB 524804 IBN 539207 ICICIBANK 524494 HDB 532174 500180 ARBQY 526797 RECLTD MANPASAND ADFFOODS

10
Market Live: Sensex, Nifty consolidate after 3-day rally; weaker rupee lifts IT stocks

2018-05-29 moneycontrol
Buzzing: After being locked in lower circuit on Monday, shares of Manpasand Beverages continued to be locked in the same band today as well, as investors continued to be wary of corporate developments. This is despite the company trying to allay fears around the controversy surrounding its auditor, Deloitte, resigning abruptly.
IPCALAB AUROPHARMA 524804 532955 532712 539207 533106 RCOM 524494 OIL HDB 500180 ARBQY 519183 526797 GREENPLY HDFCBANK RECLTD MANPASAND ADFFOODS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...